CX-2051 is a masked, conditionally activated Probody ADC that targets EpCAM, armed with a topoisomerase-1 inhibitor payload, designed to overcome safety challenges of EpCAM targeting by releasing its payload only in the tumor microenvironment. Here, EPCAM is linked to neoplasm.